MCID: VGT001
MIFTS: 55

Vogt-Koyanagi-Harada Disease

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Vogt-Koyanagi-Harada Disease

MalaCards integrated aliases for Vogt-Koyanagi-Harada Disease:

Name: Vogt-Koyanagi-Harada Disease 12 20 58 29 54 15
Uveomeningoencephalitic Syndrome 12 44 70
Vogt-Koyanagi-Harada Syndrome 20 36
Uveomenigitic Syndrome 20 58
Vogt-Koyanagi Syndrome 12
Harada's Disease 12
Vkh Syndrome 20
Vkh Disease 20

Characteristics:

Orphanet epidemiological data:

58
vogt-koyanagi-harada disease
Inheritance: Multigenic/multifactorial; Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare neurological diseases
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12297
KEGG 36 H01504
ICD9CM 34 364.24
MeSH 44 D014607
NCIt 50 C85218
SNOMED-CT 67 44923005
ICD10 32 H20.82
ICD10 via Orphanet 33 H20.8 H30.8
UMLS via Orphanet 71 C0042170
Orphanet 58 ORPHA3437
UMLS 70 C0042170

Summaries for Vogt-Koyanagi-Harada Disease

GARD : 20 Vogt-Koyanagi-Harada disease (VKH disease) affects the eyes, ears, nervous system, and skin. The symptoms of VKH occur in different phases. The early symptoms include headaches, eye pain, and dizziness. These are followed by hearing loss and inflammation of the eye ( panuveitis ). Later symptoms include development of white patches of skin and hair ( vitiligo ), hair loss ( alopecia ), cataracts, and glaucoma. The exact cause of VKH disease is unknown, but the symptoms are thought to be due to an abnormal response of the immune system to a viral infection. Genetic factors may be involved. Diagnosis of VKH disease is based on the symptoms, clinical exam, and imaging studies. Other more common diseases may need to excluded before a diagnosis of VKH disease is made. VKH disease is treated with corticosteroids and other medications.

MalaCards based summary : Vogt-Koyanagi-Harada Disease, also known as uveomeningoencephalitic syndrome, is related to iridocyclitis and choroiditis. An important gene associated with Vogt-Koyanagi-Harada Disease is PTPN22 (Protein Tyrosine Phosphatase Non-Receptor Type 22), and among its related pathways/superpathways are Innate Immune System and Class I MHC mediated antigen processing and presentation. The drugs Bevacizumab and Angiogenesis Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and skin, and related phenotypes are sensorineural hearing impairment and cognitive impairment

Disease Ontology : 12 An autoimmune disease that is caused by T helper cell mediated autoimmune attack of melanocytes resulting in inflammation of the inside of the eye, whitening of hair, skin pigment loss, and meningitis.

KEGG : 36 Vogt-Koyanagi-Harada syndrome (VKHS), initially described as an uveomeningoencephalitic syndrome, is a rare systemic autoimmune disease that targets melanocyte-rich tissues, such as the eye, inner ear, meninges, skin and hair. This disease is characterized by panuveitis, often associated with neurologic and cutaneous manifestations, including headache, hearing loss, vitiligo, and poliosis. VKHS is more common in individuals of pigmented skin, such as Asians, Middle Easterners, Hispanics and Native Americans. Although the exact etiology of VKHS remains unclear, it has also been postulated that such an autoimmune response might be triggered by an infectious agent in a genetically susceptible individual. Several studies have demonstrated that HLA-DR4 is strongly associated with VKHD.

Wikipedia : 73 Vogt-Koyanagi-Harada disease (VKH) is a multisystem disease of presumed autoimmune cause that affects... more...

Related Diseases for Vogt-Koyanagi-Harada Disease

Diseases related to Vogt-Koyanagi-Harada Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 493)
# Related Disease Score Top Affiliating Genes
1 iridocyclitis 31.7 IL17A IL10 HLA-B
2 choroiditis 31.6 IL17A IL10 IFNG
3 pars planitis 31.6 HLA-DRB1 HLA-B HLA-A
4 uveitis 31.5 PMEL IL2RA IL17A IL10 IFNG HLA-B
5 sympathetic ophthalmia 31.4 IL10 HLA-DRB1 HLA-DQA1
6 vitiligo-associated multiple autoimmune disease susceptibility 1 31.2 TYRP1 TYR PTPN22 PMEL IL17A HLA-B
7 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 31.0 PTPN22 IL17A IL10 IFNG
8 panuveitis 31.0 IL23R IL17A IL10 HLA-DRB1 HLA-DQB1 HLA-B
9 neuritis 30.9 IL10 IFNG HLA-DRB1 HLA-DQA1
10 halo nevi 30.8 TYR PMEL HLA-DRB1
11 conjunctivitis 30.8 IL10 IFNG HLA-B
12 chickenpox 30.7 IL10 IFNG CD8A
13 meningitis 30.7 IL17A IL10 IFNG HLA-B
14 hypopyon 30.7 IL17A IL10 HLA-B
15 spondyloarthropathy 1 30.6 IL23R IL17A HLA-B
16 chorioretinitis 30.6 IL17A IL10 IFNG CD8A
17 relapsing polychondritis 30.6 IL17A IL10 IFNG
18 eye disease 30.6 TYR IL17A IL10 IFNG CD8A
19 autoimmune uveitis 30.6 IL17A IL10 IFNG
20 mycobacterium tuberculosis 1 30.6 IL17A IL10 IFNG CD8A
21 proteasome-associated autoinflammatory syndrome 1 30.6 IL17A IL10 IFNG
22 intermediate uveitis 30.5 IL2RA IL10 IFNG HLA-DRB1 HLA-B
23 brucellosis 30.5 PTPN22 IL17A IL10 IFNG
24 primary adrenal insufficiency 30.5 HLA-DRB1 HLA-DQB1 HLA-DQA1
25 ulcerative colitis 30.5 IL23R IL17A IL10 IFNG HLA-DRB1
26 colitis 30.5 IL23R IL17A IL10 IFNG HLA-DRB1
27 exanthem 30.5 IL10 IFNG CD8A
28 optic neuritis 30.5 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-A
29 iritis 30.4 IL17A IL10 HLA-B CD8A
30 dermatitis 30.4 IL17A IL10 IFNG CD8A
31 fungal meningitis 30.4 IL17A IL10 IFNG CD8A
32 thyroiditis 30.4 PTPN22 IL17A IL10 IFNG HLA-DRB1
33 sarcoidosis 1 30.4 IL2RA IFNG HLA-DRB1 HLA-DQB1 HLA-A CD8A
34 reactive arthritis 30.4 IL17A IL10 IFNG HLA-DRB1 HLA-B
35 systemic scleroderma 30.4 IL17A IL10 IFNG CD8A
36 herpes zoster 30.3 IL10 IFNG HLA-DRB1 HLA-B HLA-A CD8A
37 measles 30.3 IL2RA IFNG HLA-DRB1 HLA-DQA1 HLA-A
38 disease by infectious agent 30.3 IL17A IL10 IFNG CD8A
39 spondylitis 30.3 IL23R IL17A IL10 IFNG HLA-B
40 demyelinating disease 30.3 IL17A IL10 IFNG HLA-DRB1 CD8A
41 myasthenia gravis 30.2 IL10 IFNG HLA-DQB1 HLA-B
42 syphilis 30.2 IL17A IFNG HLA-DRB1 FAS CD8A
43 viral hepatitis 30.2 IL10 IFNG HLA-DRB1 HLA-DQA1 FAS
44 toxoplasmosis 30.2 IL10 IFNG HLA-DQB1 HLA-DQA1
45 bone inflammation disease 30.1 PTPN22 IL17A IL10 IFNG HLA-DRB1 CD8A
46 sjogren syndrome 30.1 IL2RA IL10 FAS
47 skin disease 30.1 TYR IL17A IL10 IFNG HLA-B CD8A
48 guillain-barre syndrome 30.0 IL17A HLA-DRB1 HLA-DQB1 HLA-DQA1 FAS
49 crohn's disease 29.9 PTPN22 IL2RA IL23R IL17A IL10 IFNG
50 rubella 29.9 IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B

Graphical network of the top 20 diseases related to Vogt-Koyanagi-Harada Disease:



Diseases related to Vogt-Koyanagi-Harada Disease

Symptoms & Phenotypes for Vogt-Koyanagi-Harada Disease

Human phenotypes related to Vogt-Koyanagi-Harada Disease:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 sensorineural hearing impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0000407
2 cognitive impairment 58 31 hallmark (90%) Very frequent (99-80%) HP:0100543
3 vitiligo 58 31 hallmark (90%) Very frequent (99-80%) HP:0001045
4 premature graying of hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0002216
5 sparse scalp hair 58 31 hallmark (90%) Very frequent (99-80%) HP:0002209
6 hypopigmented skin patches 58 31 hallmark (90%) Very frequent (99-80%) HP:0001053
7 poliosis 58 31 hallmark (90%) Very frequent (99-80%) HP:0002290
8 abnormal eyelash morphology 31 hallmark (90%) HP:0000499
9 abnormal eyebrow morphology 31 hallmark (90%) HP:0000534
10 cataract 58 31 frequent (33%) Frequent (79-30%) HP:0000518
11 visual impairment 58 31 frequent (33%) Frequent (79-30%) HP:0000505
12 short stature 58 31 frequent (33%) Frequent (79-30%) HP:0004322
13 glaucoma 58 31 frequent (33%) Frequent (79-30%) HP:0000501
14 retinal detachment 58 31 frequent (33%) Frequent (79-30%) HP:0000541
15 abnormality of the eyelashes 58 Very frequent (99-80%)
16 abnormality of the eyebrow 58 Very frequent (99-80%)

GenomeRNAi Phenotypes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

26 (show all 36)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-102 10.05 KIR3DL3
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-103 10.05 HLA-A HLA-B
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-110 10.05 HLA-A HLA-B
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 10.05 KIR3DL3
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-139 10.05 KIR3DL3
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 10.05 KIR3DL3
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-156 10.05 HLA-A HLA-B
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-178 10.05 HLA-A HLA-B
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-19 10.05 HLA-A HLA-B
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-190 10.05 KIR3DL3
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-202 10.05 KIR3DL3
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 10.05 KIR3DL3
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 10.05 KIR3DL3
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-31 10.05 HLA-A HLA-B KIR3DL3
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-7 10.05 HLA-A HLA-B
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-73 10.05 KIR3DL3
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-79 10.05 KIR3DL3
18 Increased shRNA abundance (Z-score > 2) GR00366-A-104 9.64 IL2RA
19 Increased shRNA abundance (Z-score > 2) GR00366-A-110 9.64 HLA-DQA1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.64 IL2RA
21 Increased shRNA abundance (Z-score > 2) GR00366-A-118 9.64 HLA-A HLA-B
22 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.64 IL2RA
23 Increased shRNA abundance (Z-score > 2) GR00366-A-130 9.64 IL2RA
24 Increased shRNA abundance (Z-score > 2) GR00366-A-138 9.64 IL2RA
25 Increased shRNA abundance (Z-score > 2) GR00366-A-174 9.64 IL2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-193 9.64 HLA-DQA1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-202 9.64 IL2RA
28 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.64 IL2RA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.64 IL2RA
30 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.64 HLA-DQA1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-46 9.64 IL2RA
32 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.64 IL2RA
33 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.64 IL2RA
34 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.64 HLA-DQA1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.64 HLA-A HLA-B
36 Increased shRNA abundance (Z-score > 2) GR00366-A-98 9.64 HLA-DQA1

MGI Mouse Phenotypes related to Vogt-Koyanagi-Harada Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.03 CD8A FAS HLA-A HLA-DQA1 HLA-DQB1 IFNG
2 hematopoietic system MP:0005397 9.97 CD8A FAS HLA-A HLA-DQA1 HLA-DQB1 IFNG
3 digestive/alimentary MP:0005381 9.92 FAS HLA-DQB1 IFNG IL10 IL17A IL23R
4 immune system MP:0005387 9.73 CD8A FAS HLA-A HLA-DQA1 HLA-DQB1 IFNG
5 no phenotypic analysis MP:0003012 9.17 HLA-A IFNG IL10 IL17A IL23R PMEL

Drugs & Therapeutics for Vogt-Koyanagi-Harada Disease

Drugs for Vogt-Koyanagi-Harada Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 27)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 3 216974-75-3
2 Angiogenesis Inhibitors Phase 3
3 Antineoplastic Agents, Immunological Phase 3
4
Povidone Approved 9003-39-8 131751496
5
Povidone-iodine Approved 25655-41-8
6
Mycophenolic acid Approved 24280-93-1 446541
7
Azathioprine Approved 446-86-6 2265
8
Iodine Approved, Investigational 7553-56-2 807
9
Methylprednisolone Approved, Vet_approved 83-43-2 6741
10
Methylprednisolone hemisuccinate Approved 2921-57-5
11
Prednisolone Approved, Vet_approved 50-24-8 5755
12
Prednisolone acetate Approved, Vet_approved 52-21-1
13
Prednisone Approved, Vet_approved 53-03-2 5865
14
Prednisolone phosphate Approved, Vet_approved 302-25-0
15
Cadexomer iodine Experimental 94820-09-4
16
Prednisolone hemisuccinate Experimental 2920-86-7
17 Immunologic Factors
18 Immunosuppressive Agents
19 Anti-Bacterial Agents
20 Antibiotics, Antitubercular
21 Cyclosporins
22 Hormones
23 Methylprednisolone Acetate
24 Antineoplastic Agents, Hormonal
25 Hormone Antagonists
26 glucocorticoids
27 Anti-Inflammatory Agents

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Intravitreal Bevacizumab for the Treatment of Neovascular Membranes in Patients With Intraocular Inflammation Completed NCT00407121 Phase 3 Bevacizumab
2 Influência de imunomodulação Precoce Influence of Early Immunosuppressive Therapy on the Course of Vogt-Koyanagi-Harada Disease: a Prospective Study Unknown status NCT03399175 Early high-dose corticosteroid and immunosuppressive therapy
3 Intravitreal Bevacizumab for the Treatment of Choroidal Neovascularization in Vogt-Koyanagi-Harada Disease - A Prospective Study Unknown status NCT02015351 bevacizumab
4 Multimodal Analysis and Electroretinogram in VKH From Acute Onset - a Prospective Study Completed NCT03811366 Meticorten
5 Clinical Observational Research on Changes of Peripheral Blood Mononuclear Cell(PBMC) Immunity and Expression Profile in Peripheral Blood of Different Course of of Vogt-Hoyanagi-Harada(VKH) Patients. Recruiting NCT04025476 Steroids
6 Using Next-Generation Sequencing Technology to Identify Biomarkers of Common Eye Diseases Recruiting NCT04101604
7 Pilot Project: The Amplicon and Metatranscriptomic Next-generation Sequencing of Samples From Intra and Extra-intestinal Microbiome in Non-infectious Uveitis Patients to Decipher Possibility Uveitis Pathogenesis Not yet recruiting NCT04126850

Search NIH Clinical Center for Vogt-Koyanagi-Harada Disease

Cochrane evidence based reviews: uveomeningoencephalitic syndrome

Genetic Tests for Vogt-Koyanagi-Harada Disease

Genetic tests related to Vogt-Koyanagi-Harada Disease:

# Genetic test Affiliating Genes
1 Vogt-Koyanagi-Harada Disease 29

Anatomical Context for Vogt-Koyanagi-Harada Disease

MalaCards organs/tissues related to Vogt-Koyanagi-Harada Disease:

40
Eye, Retina, Skin, Lung, T Cells, Myeloid, Spinal Cord

Publications for Vogt-Koyanagi-Harada Disease

Articles related to Vogt-Koyanagi-Harada Disease:

(show top 50) (show all 780)
# Title Authors PMID Year
1
Expression of Fas antigen on helper T lymphocytes in Vogt-Koyanagi-Harada disease. 61 54
9646088 1998
2
Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. 61 54
9510558 1998
3
Apoptosis-related fas antigen on memory T cells in aqueous humor of uveitis patients. 61 54
8654110 1996
4
Influence of HLA-DRB1 gene variation on the clinical course of Vogt-Koyanagi-Harada disease. 61 54
7906684 1994
5
Characterization of T-cell subsets, soluble interleukin-2 receptors and interleukin-6 in Vogt-Koyanagi-Harada disease. 61 54
1635294 1992
6
Development of Vogt-Koyanagi-Harada Disease-like Uveitis during Treatment by Anti-programmed Death Ligand-1 Antibody for Non-small Cell Lung Cancer: A Case Report. 61
33797309 2021
7
BACILLARY LAYER DETACHMENT IN ACUTE VOGT-KOYANAGI-HARADA DISEASE: A Novel Swept-Source Optical Coherence Tomography Analysis. 61
32833410 2021
8
Efficacy of Rituximab Treatment in Vogt-Koyanagi-Harada Disease Poorly Controlled by Traditional Immunosuppressive Treatment. 61
33793383 2021
9
Delayed diagnosis of myelitis in a patient with Vogt-Koyanagi-Harada disease: a case report. 61
33788652 2021
10
Effect of immunosuppressive therapy on ocular blood flow in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease. 61
33719161 2021
11
Vogt-Koyanagi-Harada disease in a Native American population in Oklahoma. 61
33403519 2021
12
Acute lymphocytic leukemia with initial manifestation of serous retinal detachment and choroidal thickening: case report and literature review. 61
33765851 2021
13
Epidemiology of uveitis in Japan: a 2016 retrospective nationwide survey. 61
33694024 2021
14
CHOROIDAL GRANULOMAS VISUALIZED BY SWEPT-SOURCE OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY. 61
32467485 2021
15
Headache and Bilateral Optic Disc Edema as the Initial Manifestation of Vogt-Koyanagi-Harada Disease. 61
32102009 2021
16
Recent Clinical Features of Intraocular Inflammation in Hokkaido, Japan - Comparison with the Previous Decade. 61
33571416 2021
17
Effect of immunosuppressive therapy on oxygen saturation and diameter of retinal vessels in initial onset acute uveitis associated with Vogt-Koyanagi-Harada disease. 61
32592327 2021
18
Iris Manifestations in Inadequately Treated Chronic Recurrent Vogt-Koyanagi-Harada Disease. 61
33561370 2021
19
Vogt-Koyanagi-Harada disease is always bilateral: reports of unilateral cases failed to use choroidal investigations showing subclinical involvement of the fellow eye. 61
33559795 2021
20
Efficacy and Safety of Adalimumab Therapy for the Treatment of Non-infectious Uveitis: Efficacy comparison among Uveitis Aetiologies. 61
33560160 2021
21
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis. 61
33527798 2021
22
Comments on: Vogt - Koyanagi - Harada disease associated with anterior ischemic optic neuropathy in a young woman presenting as acute angle-closure glaucoma. 61
33323630 2021
23
Response to comments on: Vogt-Koyanagi-Harada disease associated with anterior ischemic optic neuropathy in a young woman presenting as acute angle-closure glaucoma. 61
33323631 2021
24
Role of optical coherence tomography angiography in Vogt-Koyanagi-Harada disease. 61
33796433 2021
25
[Autofluorescence combined with spectral domain optical coherence tomography for diagnosis and follow-up of acute Vogt-Koyanagi-Harada disease]. 61
33509766 2021
26
Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease. 61
31638886 2021
27
MRI Choroidal Thickening as Presenting Sign of Vogt-Koyanagi-Harada Disease. 61
33512834 2021
28
Impact of Inflammation and Treatment on Self-reported Quality of Life in Patients with Non-acute Vogt-Koyanagi-Harada Disease (VKHD). 61
31671020 2021
29
Identification of Urine Metabolic Biomarkers for Vogt-Koyanagi-Harada Disease. 61
33718374 2021
30
Changes in choroidal imaging parameters following adalimumab therapy for refractory noninfectious uveitis. 61
33415356 2021
31
Activation of the interleukin-23/interleukin-17 signalling pathway in autoinflammatory and autoimmune uveitis. 61
32422390 2021
32
Role of Optical Coherence Tomography in the Prognosis of Vogt-Koyanagi-Harada Disease. 61
31577462 2021
33
Prevalence and clinical features of systemic diseases in Chinese patients with uveitis. 61
32188681 2021
34
Comparing the Results of Vitrectomy and Sclerectomy in a Patient with Nanophthalmic Uveal Effusion Syndrome. 61
33572746 2021
35
Vogt-Koyanagi-Harada Disease: A Case Series in a Tertiary Eye Center. 61
33552608 2021
36
Serum Metabolomic Profiling of Patients with Non-Infectious Uveitis. 61
33291298 2020
37
Proliferative retinopathy as a feature of Vogt Koyanagi Harada Disease: a report of two cases. 61
33261580 2020
38
Vogt-Koyanagi-Harada Disease Managed With Immunomodulatory Therapy Within 3 Months of Disease Onset. 61
32738228 2020
39
Three-dimensional analysis of choroidal vessels in eyes with Vogt-Koyanagi-Harada disease before and after treatment. 61
32835675 2020
40
Diagnostic Value of Optical Coherence Tomography in the Early Diagnosis of Macular Complications in Chronic Vogt-Koyanagi-Harada Disease. 61
33136534 2020
41
Mycophenolate sodium in the treatment of corticosteroid-refractory non-infectious inflammatory uveitis (MySTRI study). 61
32632297 2020
42
Clinical Presentation, Management, and Long-Term Outcome of Pars Planitis, Panuveitis, and Vogt-Koyanagi-Harada Disease in Children and Adolescents. 61
31444859 2020
43
Analysis of Three-Dimensional Choroidal Volume with Enhanced Depth Imaging Findings in Patients with Recurrent Vogt-Koyanagi-Harada Disease. 61
33215546 2020
44
Prevalence, risk factors and management of ocular hypertension or glaucoma in patients with Vogt-Koyanagi-Harada disease. 61
33011689 2020
45
Predictive Biomarker for Progression Into the Sunset Glow Fundus of Vogt-Koyanagi-Harada Disease, Using Adaptive Binarization of Fundus Photographs. 61
33133773 2020
46
Evaluation of microvasculature alterations in convalescent Vogt-Koyanagi-Harada disease using optical coherence tomography angiography. 61
33024324 2020
47
Correlation between Subfoveal Choroidal Thickness and Anterior Segment Inflammation in Patients with Chronic Stage of Vogt-Koyanagi-Harada Disease. 61
33021859 2020
48
Vogt-Koyanagi-Harada disease: a retrospective and multicentric study of 41 patients. 61
33028239 2020
49
Associations between functional and structural measurements in non-acute Vogt-Koyanagi-Harada disease. 61
33124155 2020
50
A case of Vogt-Koyanagi-Harada-like uveitis secondary to dabrafenib/trametinib therapy for advanced melanoma. 61
32998540 2020

Variations for Vogt-Koyanagi-Harada Disease

Expression for Vogt-Koyanagi-Harada Disease

Search GEO for disease gene expression data for Vogt-Koyanagi-Harada Disease.

Pathways for Vogt-Koyanagi-Harada Disease

Pathways related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 42)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.99 PTPN22 KIR3DL2 KIR3DL1 IL2RA IL23R IL17A
2
Show member pathways
13.45 PTPN22 KIR3DL2 KIR3DL1 HLA-DRB1 HLA-DQB1 HLA-DQA1
3
Show member pathways
13.29 IL2RA IL23R IL17A IL10 IFNG HLA-DRB1
4
Show member pathways
12.92 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
5 12.81 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
6
Show member pathways
12.68 IL2RA IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B
7
Show member pathways
12.65 IL2RA IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
8
Show member pathways
12.6 IL17A IL10 IFNG FAS CD8A
9
Show member pathways
12.54 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
10 12.49 PTPN22 IL2RA IL17A IL10 IFNG FAS
11
Show member pathways
12.38 IL2RA IL23R IL10 IFNG
12
Show member pathways
12.36 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1
13
Show member pathways
12.34 KIR3DL3 KIR3DL2 KIR3DL1 IFNG HLA-B HLA-A
14 12.33 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
15
Show member pathways
12.32 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1
16
Show member pathways
12.3 IL2RA IL23R IL17A IL10 IFNG HLA-DRB1
17
Show member pathways
12.29 IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
18
Show member pathways
12.29 IL2RA IL17A IL10 IFNG HLA-B HLA-A
19 12.26 IL10 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
20
Show member pathways
12.21 KIR3DL3 KIR3DL2 KIR3DL1 IL2RA IL17A IL10
21 12.16 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
22 12.09 KIR3DL2 KIR3DL1 HLA-B HLA-A CD8A
23 12.01 IL2RA IL10 IFNG CD8A
24
Show member pathways
11.99 IL2RA IFNG HLA-DRB1 HLA-A CD8A
25
Show member pathways
11.97 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1
26 11.91 IL10 HLA-DRB1 HLA-DQB1 HLA-DQA1
27 11.91 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A CD8A
28 11.89 IL2RA HLA-DRB1 HLA-DQB1 HLA-DQA1 CD8A
29
Show member pathways
11.82 IL23R IL17A IFNG
30 11.82 IL17A IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1
31
Show member pathways
11.79 HLA-DRB1 HLA-DQB1 HLA-DQA1
32
Show member pathways
11.73 IL17A IL10 IFNG
33 11.72 IL10 IFNG CD8A
34
Show member pathways
11.68 IL2RA IFNG HLA-A CD8A
35 11.65 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1 CD8A
36 11.5 IL2RA IL10 IFNG
37 11.4 IL10 IFNG FAS
38
Show member pathways
11.38 IL2RA IL10 IFNG FAS
39 11.34 IL2RA IL23R IL17A IL10 IFNG CD8A
40 11.28 IL10 IFNG HLA-DRB1
41 11.26 IL2RA IFNG HLA-DRB1
42 10.36 TYRP1 TYR

GO Terms for Vogt-Koyanagi-Harada Disease

Cellular components related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005886 10.27 PMEL KIR3DL3 KIR3DL2 KIR3DL1 IL2RA IL23R
2 integral component of membrane GO:0016021 10.24 TYRP1 TYR PMEL KIR3DL3 KIR3DL2 KIR3DL1
3 integral component of plasma membrane GO:0005887 10.01 PMEL KIR3DL2 KIR3DL1 HLA-DRB1 HLA-DQA1 HLA-B
4 external side of plasma membrane GO:0009897 9.8 IL2RA IL23R IL17A HLA-DRB1 FAS CD8A
5 trans-Golgi network membrane GO:0032588 9.7 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 endocytic vesicle membrane GO:0030666 9.65 HLA-DRB1 HLA-DQB1 HLA-DQA1
7 transport vesicle membrane GO:0030658 9.61 HLA-DRB1 HLA-DQB1 HLA-DQA1
8 melanosome membrane GO:0033162 9.51 TYRP1 TYR
9 MHC class I protein complex GO:0042612 9.49 HLA-B HLA-A
10 clathrin-coated endocytic vesicle membrane GO:0030669 9.46 TYRP1 HLA-DRB1 HLA-DQB1 HLA-DQA1
11 MHC class II protein complex GO:0042613 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1
12 ER to Golgi transport vesicle membrane GO:0012507 9.35 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
13 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A

Biological processes related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.96 PTPN22 IL2RA IL23R IL17A HLA-DRB1 HLA-DQB1
2 adaptive immune response GO:0002250 9.92 IL17A IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B
3 regulation of immune response GO:0050776 9.89 KIR3DL2 KIR3DL1 HLA-B HLA-A CD8A
4 T cell receptor signaling pathway GO:0050852 9.88 PTPN22 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-A
5 positive regulation of interferon-gamma production GO:0032729 9.77 PTPN22 IL23R HLA-A
6 negative regulation of T cell proliferation GO:0042130 9.73 IL2RA IL10 HLA-DRB1
7 positive regulation of interleukin-12 production GO:0032735 9.71 IL23R IL17A IFNG
8 positive regulation of osteoclast differentiation GO:0045672 9.69 IL23R IL17A IFNG
9 positive regulation of T cell mediated cytotoxicity GO:0001916 9.67 IL23R HLA-DRB1 HLA-B HLA-A
10 positive regulation of signaling receptor activity GO:2000273 9.63 IL10 IFNG
11 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.63 HLA-DRB1 HLA-DQB1 HLA-DQA1
12 interferon-gamma-mediated signaling pathway GO:0060333 9.63 IFNG HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A
13 positive regulation of MHC class II biosynthetic process GO:0045348 9.62 IL10 IFNG
14 positive regulation of memory T cell differentiation GO:0043382 9.62 IL23R HLA-DRB1
15 antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent GO:0002480 9.61 HLA-B HLA-A
16 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.61 HLA-B HLA-A
17 melanin biosynthetic process GO:0042438 9.61 TYRP1 TYR PMEL
18 protection from natural killer cell mediated cytotoxicity GO:0042270 9.59 HLA-B HLA-A
19 activation-induced cell death of T cells GO:0006924 9.58 IL2RA FAS
20 humoral immune response mediated by circulating immunoglobulin GO:0002455 9.58 HLA-DRB1 HLA-DQB1
21 detection of bacterium GO:0016045 9.58 HLA-DRB1 HLA-B HLA-A
22 positive regulation of interleukin-23 production GO:0032747 9.57 IL17A IFNG
23 positive regulation of CD8-positive, alpha-beta T cell proliferation GO:2000566 9.55 PTPN22 HLA-A
24 immunoglobulin production involved in immunoglobulin mediated immune response GO:0002381 9.52 HLA-DRB1 HLA-DQB1
25 antigen processing and presentation GO:0019882 9.43 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A CD8A
26 immune response GO:0006955 9.4 KIR3DL1 IL2RA IL17A IL10 IFNG HLA-DRB1

Molecular functions related to Vogt-Koyanagi-Harada Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.26 TYRP1 TYR PTPN22 PMEL KIR3DL3 KIR3DL2
2 T cell receptor binding GO:0042608 9.37 HLA-DRB1 HLA-A
3 TAP binding GO:0046977 9.32 HLA-B HLA-A
4 monophenol monooxygenase activity GO:0004503 9.16 TYRP1 TYR
5 MHC class II receptor activity GO:0032395 9.13 HLA-DRB1 HLA-DQB1 HLA-DQA1
6 peptide antigen binding GO:0042605 9.02 HLA-DRB1 HLA-DQB1 HLA-DQA1 HLA-B HLA-A

Sources for Vogt-Koyanagi-Harada Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....